Outpatient management of cirrhosis: A narrative review

Southern Medical Journal

Volumn 99, Issue 6, 2006, Pages 600-606

  Mathews Jr , Ronnie E ^a   McGuire, Brendan M ^a   Estrada, Carlos A ^a  

^a MCLM 262A ^*

Author keywords

Ascites; Cirrhosis; Esophageal varices; Hepatocellular carcinoma; Outpatient management

Indexed keywords

HERBACEOUS AGENT; MIDODRINE; OCTREOTIDE; RETINOL; SENNA EXTRACT;

ASCITES; BACTERIAL PERITONITIS; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; ESOPHAGUS VARICES; HEPATOPULMONARY SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; KIDNEY BLOOD FLOW; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; OUTPATIENT CARE; PATIENT EDUCATION; REVIEW; SENSITIVITY AND SPECIFICITY;

AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTIC PROPHYLAXIS; ASCITES; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PERITONITIS; RECURRENCE;

EID: 33745683760     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000220889.36995.54     Document Type: Review

References (55)

1. Kochanek KD, Murphy SL, Anderson RN, et al. Deaths: final data for 2002. Natl Vital Stat Rep 2004;53:1-115.
2. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2005;158:1-199.
3. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
4. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992;21:149-161.
5. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982;82:968-973.
6. de Dombal FT, Clarke JR, Clamp SE, et al Prognostic factors in upper GI bleeding. Endoscopy 1986;18 (Suppl 2):6-10.
7. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-809.
8. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
9. Lowe RC, Grace ND. Primary prophylaxis of variceal hemorrhage. Clin Liver Dis 2001;5:665-676.
10. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study: the North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. N Engl J Med 1988;319:983-989.
11. Arguedas MR, Heudebert GR, Eloubeidi MA, et al. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 2002;97:2441-2452.
12. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.
13. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72.
14. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25:63-70.
15. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000;32:461-465.
16. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128.
17. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-220.
18. McGuire BM, Bloomer JR. Complications of cirrhosis: why they occur and what to do about them. Postgrad Med 1998;103:209-12, 217-8, 223-224.
19. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-475.
20. Rosemurgy AS, Zervos EE, Clark WC, et al. TIPS versus peritone-ovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004;239:883-891.
21. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171-175.
22. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document: International Ascites Club. J Hepatol 2000;32:142-153.
23. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31.
24. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-724.
25. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
26. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680.
27. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients: Cancer of the Liver Italian Program. Hepatology 2001;34:529-534.
28. Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266-2273.
29. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
30. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.
31. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002;36:S84-S92.
32. Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001;5:123-144.
33. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-690.
34. Arguedas MR. Screening for hepatocellular carcinoma: why, when, how? Curr Gastroenterol Rep 2003;5:57-62.
35. Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996;24:556-560.
36. Sood GK, Sarin SK, Mahaptra J, et al. Comparative efficacy of psychometric tests in detection of subclinical hepatic encephalopathy in non-alcoholic cirrhotics: search for a rational approach. Am J Gastroenterol 1989;84:156-159.
37. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479.
38. Plauth M, Merli M, Kondrup J. Management of hepatic encephalopathy. N Engl J Med 1997;337:1921-1922.
39. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43.
40. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-205.
41. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404-1406.
42. Arguedas MR, Johnson A, Eloubeidi MA, et al. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001;34:28-31.
43. Carson JL, Willett LR Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs 1993;46 (Suppl 1):243-248.
44. Riley TR III, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998;93:1563-1565.
45. Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med 1999;14:699-704.
46. Tong W, Hurley S, Hayashi PH. Reconsidering hepatorenal syndrome: throw in the towel? Not so fast! Postgrad Med 2004;116:15-6, 21-24.
47. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
48. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
49. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-430.
50. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109:1283-1288.
51. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042-1052.
52. Arguedas MR, Abrams GA, Krowka MJ, et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37:192-197.
53. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
54. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
55. Murray KF, Carithers RL Jr. ASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-1432.